EGFR and non-small cell lung carcinoma: Among cases with EGFR mutations, approximately 48% (15/31) of NSCLC patients exhibited thoracic confinement, suggesting that these individuals could potentially benefit from early surgical intervention or targeted drug therapy to enhance survival rates.